| 别名 CHETK-alpha、CHKA、ChoKα + [5] | 
| 简介 Plays a key role in phospholipid biosynthesis by catalyzing the phosphorylation of free choline to phosphocholine, the first step in phosphatidylcholine biosynthesis (PubMed:17007874, PubMed:19915674, PubMed:23416529, PubMed:34077757). Also phosphorylates ethanolamine, thereby contributing to phosphatidylethanolamine biosynthesis (PubMed:17007874, PubMed:19915674). Has higher activity with choline (PubMed:17007874, PubMed:19915674). May contribute to tumor cell growth (PubMed:19915674).
This isoform plays a key role in lipolysis of lipid droplets following glucose deprivation (PubMed:34077757). In response to glucose deprivation, phosphorylated by AMPK, promoting localization to lipid droplets (PubMed:34077757). Phosphorylation is followed by acetylation by KAT5, leading to dissociation of the homodimer into a monomer (PubMed:34077757). Monomeric CHKA isoform 1 is converted into a tyrosine-protein kinase, which phosphorylates lipid droplet structural proteins PLIN2 and PLIN3, leading to lipolysis of lipid droplets (PubMed:34077757). | 
| 作用机制 CHKA抑制剂 [+1]  | 
| 在研适应症 | 
| 非在研适应症- | 
| 最高研发阶段临床前 | 
| 首次获批国家/地区- | 
| 首次获批日期1800-01-20 | 
| 靶点 | 
| 作用机制 CHKA抑制剂 | 
| 在研机构- | 
| 在研适应症- | 
| 非在研适应症 | 
| 最高研发阶段无进展 | 
| 首次获批国家/地区- | 
| 首次获批日期1800-01-20 | 
| 靶点 | 
| 作用机制 CHKA抑制剂 | 
| 在研机构- | 
| 在研适应症- | 
| 非在研适应症 | 
| 最高研发阶段无进展 | 
| 首次获批国家/地区- | 
| 首次获批日期1800-01-20 | 
| 开始日期2011-01-01 | 
